We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| BeiGene Ltd | NASDAQ:BGNE | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.73 | -0.45% | 162.54 | 160.00 | 164.00 | 165.50 | 161.70 | 163.82 | 101,477 | 23:24:19 |
From Jul 2022 to Jul 2024
By Sabela Ojea
BeiGene Ltd. said Monday that a European Medicines Agency committee has recommended granting marketing authorization for its Brukinsa drug, aimed at treating adults diagnosed with a marginal zone lymphoma.
The biotechnology company said the European Union's Committee for Medicinal Products for Human Use has a positive opinion on the Brukinsa inhibitor.
"With this positive opinion, we are one step closer to bringing forward a chemotherapy-free treatment option for this rare blood cancer," said Mehrdad Mobasher, BeiGene's chief medical officer of hematology.
Marginal zone lymphoma is a group of ultra-rare, slow growing B-cell malignancies that begin in the marginal zones of lymph tissue. BeiGene said the incidence rate is estimated to range between 20 million and 30 per million a year.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
September 19, 2022 08:15 ET (12:15 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year BeiGene Chart |
1 Month BeiGene Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
